Home › Neurofibrosarcoma
Neurofibrosarcoma clinical trials recruiting in the U.S.
14 studies for Neurofibrosarcoma are recruiting participants at sites across the United States.
Cities with the most studies
- Washington, DC6 studies
- New York City, NY6 studies
- Boston, MA4 studies
- St. Louis, MO4 studies
- Mountain View, CA3 studies
- Cincinnati, OH3 studies
- Edison, NJ3 studies
- Queens, NY3 studies
- Chicago, IL3 studies
- Houston, TX3 studies
By state
- California3 studies
- Illinois3 studies
- Maryland4 studies
- Massachusetts5 studies
- Missouri4 studies
- New Jersey3 studies
- New York6 studies
- Ohio4 studies
- Tennessee4 studies
- Texas5 studies
Recently updated studies
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RecruitingPhase 1
Ages 12 to 120 · All sexes · Updated Sep 23, 2026 · NCT04222413DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
RecruitingObservational study
Ages 1 and older · All sexes · Updated Sep 18, 2026 · NCT07298083Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05732831Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT05245500Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
RecruitingObservational study
Ages 3 to 120 · All sexes · Updated Sep 2, 2026 · NCT06222203Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
RecruitingPhase 2
Ages 18 to 99 · All sexes · Updated Aug 24, 2026 · NCT05253131Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 11, 2026 · NCT07549022SPEARHEAD-3 Pediatric Study
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Aug 3, 2026 · NCT06239272Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 27, 2026 · NCT06735820B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RecruitingPhase 2
12 Months · All sexes · Updated May 6, 2026 · NCT05985161Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
RecruitingObservational study
All ages · All sexes · Updated Mar 9, 2026 · NCT03141021A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
RecruitingPhase 2
Ages 16 and older · All sexes · Updated Feb 5, 2026 · NCT04872543From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.